Achieve Life Sciences, Inc. (NASDAQ:ACHV) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of securities and milestone warrants Update: US$180M–US$354M Use of proceeds: Development and launch of cytisinicline, if approved, for nicotine dependence | Apr 16, 2026 |
| Public offering of common stock and accompanying common warrants Closed: US$45M raised · US$3 a share · Warrants at US$3 for 60 months · Citizens Capital Markets +2 Dealers: Citizens Capital Markets (co-lead), Raymond James (co-lead), Lake Street Capital Markets, LLC Use of proceeds: Advance cytisinicline through potential FDA marketing approval, plus working capital and general corporate purposes | Jun 30, 2025 |